Related Experiment Videos
[Purpura fulminans. A fatal consequence of a widely used medication?]
U R Hengge1, C Jochum, E Tschakarjan
1Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen, Germany. ulrich.hengge@uni-esen.de
Abstract:
A 39-year old man developed purpura fulminans, a manifestation of disseminated intravascular coagulopathy, with rhabdomyolsis following the i.m. injection of diclofenac.
Insights
A rare case of purpura fulminans and rhabdomyolysis occurred in a 39-year-old man after an intramuscular injection of diclofenac. This highlights a severe adverse reaction to the commonly used nonsteroidal anti-inflammatory drug.
Area of Science:
- Pharmacology
- Toxicology
- Clinical Medicine
Background:
- Diclofenac is a widely used nonsteroidal anti-inflammatory drug (NSAID).
- Intramuscular administration is a common route for diclofenac delivery.
- Disseminated intravascular coagulopathy (DIC) and rhabdomyolysis are serious medical conditions.
Observation:
- A 39-year-old male patient presented with purpura fulminans.
- Purpura fulminans is a clinical manifestation of severe coagulopathy.
- The patient had recently received an intramuscular injection of diclofenac.
Findings:
- The patient developed purpura fulminans and rhabdomyolysis.
- These severe conditions were temporally associated with the diclofenac injection.
- This suggests a potential causal link between diclofenac administration and these adverse events.
Implications:
- This case underscores the potential for severe, life-threatening adverse reactions to diclofenac.
- Healthcare providers should be aware of this rare but serious complication.
- Further investigation into the mechanisms of diclofenac-induced coagulopathy and myopathy may be warranted.